alexa Abstract | Genistein Produces Hepatoprotection through Modulating EGFR Expression and Phosphorylation in Experimental Fibrosis
ISSN: 2167-0889

Journal of Liver
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Background and Objective: Liver disease chronicity leads to the appearance of fibrosis, cirrhosis, and eventually cancer. For this reason, it is important to research new fibrosis therapies. The use of genistein as a hepatoprotective agent has been studied, but its mechanism of action is unknown. The aim of this work was to evaluate the role of genistein as a fibrosis treatment and its possible mechanism of action through CCl4-induced inhibition of EGFR in rat specimens. Methods: Hepatic fibrosis was brought about by chronic administration of CCl4 to rats. Animals with fibrosis were treated with 1 mg/kg genistein. To evaluate the hepatoprotection of genistein on liver fibrosis, we made a histopathological analysis using both H&E and trichrome staining, as well as an immunofluorescence analysis for α- SMA and an immunohistochemical analysis for PCNA. In order to find out the effects of genistein on EGFR expression and phosphorylation, we performed immunostaining for EGFR and dot blot analysis for two specific tyrosine residues: pY992 and pY1068. We also evaluated liver functionality. Results: Genistein reduced liver fibrosis and improved liver architecture. α-SMA positive cells were lower in genistein-treated animals with fibrosis. Likewise we found a reduction in EGFR expression and phosphorylation of genistein-treated animals with fibrosis; PCNA positive cells were reduced in this group. We observed liver functionality improvement in those animals with fibrosis that were treated with genistein. Conclusion: Genistein produces hepatoprotection through modulating the expression and phosphorylation of EGFR in experimental fibrosis.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Rodriguez Fragoso L, Alvarez Ayala E, García Vazquez F and Reyes Esparza J


&alpha,-SMA, EGFR, Fibrosis, Hepatoprotection, PCNA, Liver Cirrhosis, Liver Damage, Liver Disease, Liver Function, Fatty Liver, Gastrointestinal Carcinoid Tumours.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version